MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Galmed Pharmaceuticals Ltd Company Profile (NASDAQ:GLMD)

Consensus Ratings for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.50 (350.73% upside)

Analysts' Ratings History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2015MLV & Co.Reiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015SunTrustLower Price TargetBuy$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.37)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.32)($0.32)
Q2 20162($0.41)($0.38)($0.40)
Q3 20162($0.44)($0.38)($0.41)
Q4 20162($0.39)($0.33)($0.36)
(Data provided by Zacks Investment Research)
Dividend History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
DateHeadline
06/23/16 07:07 AMNew Broker Ratings For Galmed Pharmaceuticals Ltd. (GLMD) - FTSE News
06/20/16 10:29 AMGalmed Pharmaceuticals Ltd. (GLMD) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 04:14 PMRecently Issued Stock Ratings For Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard
06/08/16 10:23 PMGalmed Pharma Reports Expansion of Ongoing Phase IIb ARREST Study to China
06/08/16 04:55 AMALDX Expects Data In Q3, CATB Tumbles On Study Data, Teva Gets FDA Panel Nod
06/07/16 10:04 AMGalmed Pharmaceuticals Says Ongoing Phase IIB ARREST Trial Expanded To China -
06/07/16 07:18 AMGalmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China - [at noodls] - TEL AVIV, Israel, June 7, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
06/04/16 09:39 PMGalmed Pharmaceuticals Ltd (GLMD) Receives “Buy” Rating from HC Wainwright - Let Me Know About This
06/03/16 10:27 PMMaxim Group Reiterates Buy Rating for Galmed Pharmaceuticals Ltd (GLMD) - Let Me Know About This
06/02/16 04:27 PMGalmed Pharmaceuticals Ltd. (GLMD) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Galmed Pharmaceuticals Ltd. (GLMD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Galmed Pharmaceuticals Ltd. (GLMD). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Stock Rating ReviewThe Postall 3 news articles »
06/01/16 07:23 AMGalmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial - [at noodls] - TEL AVIV, Israel, June 1, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
05/30/16 10:41 PMStock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - HNN - Stock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Galmed Pharmaceuticals Ltd.and more »
05/30/16 10:41 PMStock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - HNN - Stock Review and Earnings Check on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Galmed Pharmaceuticals Ltd.and more »
05/27/16 11:42 AMCould Galmed Pharmaceuticals Ltd Crash Even More? The Stock Had Another Big Decline Today - Wall Street Hints and News - Could Galmed Pharmaceuticals Ltd Crash Even More? The Stock Had Another Big Decline TodayWall Street Hints and NewsThe stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is a huge mover today! The stock decreased 6.46% or $0.28 on May 26, hitting $4.12. About 61,604 shares traded hands or 287.64% up from the average. Galmed Pharmaceuticals Ltd ...
05/16/16 07:32 AMGalmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - TEL AVIV, Israel, May 16, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
05/16/16 07:15 AMGalmed Pharmaceuticals reports 1Q loss -
05/09/16 07:30 AMGalmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016 - [PR Newswire] - TEL AVIV, Israel, May 9, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
05/03/16 07:30 AMMount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disea - [at noodls] - TEL AVIV, Israel, May 3, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
04/07/16 07:22 AMGalmed Pharmaceuticals to Hold a Symposium on Non-Invasive Diagnostics during the International Liver Congress in Spain - [at noodls] - TEL AVIV, Israel, April 7, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
04/05/16 01:54 PM[$$] Gilead Buy Could Bolster Galmed Valuation -
03/30/16 07:10 AMAramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease - [at noodls] - TEL AVIV, Israel, March 30, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
03/29/16 07:15 AMGalmed Pharmaceuticals (GLMD) Jumps: Stock Rises 7.9% -
03/22/16 06:51 AMGalmed Pharmaceuticals reports 4Q loss -
03/07/16 07:30 AMGalmed Pharmaceuticals to Present at the ROTH Conference - [PR Newswire] - TEL AVIV, Israel, March 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that Josh Blacher, Chief Financial Officer, will present a company overview at the 28th Annual ROTH Conference in Orange County, California, on Monday, March 14, 2016 at 10:00 AM Pacific Standard Time. Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.
03/01/16 07:30 AMGalmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study - [PR Newswire] - TEL AVIV, Israel, March 1, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has randomized the first patient in the ARRIVE Study (ARamcholTM for the Reversal of HIV-AssociatEd Lipodystrophy and NAFLD), a proof-of-concept clinical trial that will evaluate the safety and efficacy of AramacholTM in up to 50 patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease, or NAFLD. The ARRIVE Study is a randomized, double-blinded, allocation-concealed, placebo-controlled, proof-of-concept Phase IIa clinical trial, which is an investigator-initiated study, and is being conducted at the NAFLD Research Center, University of California San Diego by Professor Rohit Loomba.
02/26/16 09:52 AMChanges To Broker Targets On Galmed Pharmaceuticals Ltd. (GLMD) - Share Trading News - Changes To Broker Targets On Galmed Pharmaceuticals Ltd. (GLMD)Share Trading News04/01/2015 – Galmed Pharmaceuticals Ltd. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 24 price target on the stock. The share price of Galmed Pharmaceuticals Ltd. (GLMD) was down -8.37% during the last trading session, ...and more »
02/21/16 01:17 PMCan Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Move Higher On Charts? - Stocks Daily - Can Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Move Higher On Charts?Stocks DailyThe research group Zacks released a report as per which Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares can hit a high of $24 in the forthcoming fiscal. Zacks included several brokerages in the poll and thereafter defined a price target of $21.6 on ...Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Shorted Shares Increased 6.84% After Market SellingRiversideGazette.comall 2 news articles »
02/15/16 12:53 PMGalmed Pharmaceuticals Ltd. (GLMD) Broker Views - Risers & Fallers - Galmed Pharmaceuticals Ltd. (GLMD) Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Galmed Pharmaceuticals Ltd. (GLMD). According to the latest broker reports outstanding on Monday 15th of February, 0 analysts have a rating of “strong buy”, 0 ...Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Short Interest Increased By 6.84%fdanewsalert.comall 3 news articles »
02/11/16 07:16 AM8:16 am Galmed Pharma Chief Medical Officer Dr. Maya Halpern to retire effective April 9 -
02/11/16 07:00 AMGalmed Pharmaceuticals Announces Retirement of Chief Medical Officer - [PR Newswire] - TEL AVIV, Israel, Feb. 11, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that its Chief Medical Officer, Dr. Maya Halpern, has notified the Company that she will retiring from Galmed as Chief Medical Officer and from its Board of Directors effective as of April 9, 2016 due to her reaching retirement age. "Dr. Halpern has been an instrumental part of growing Galmed to the point where it is today," commented President and Chief Executive Officer, Allen Baharaff. Dr. Halpern remarked, "It has been a privilege and honor to be a part of the Galmed team and helping to pave the way for a promising therapy for the treatment of NASH.
02/10/16 01:22 PMGalmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Short Interest Decreased By 9.96% - fdanewsalert.com - Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Short Interest Decreased By 9.96%fdanewsalert.comThe stock of Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) registered a decrease of 9.96% in short interest. GLMD's total short interest was 68,700 shares in February as published by FINRA. Its down 9.96% from 76,300 shares, reported previously.Bearish Gap Down for Galmed Pharmaceuticals Ltd After Worse FundamentalsSonoran Weekly Reviewall 2 news articles »
02/03/16 11:56 AMPrice Target Update On Galmed Pharmaceuticals Ltd. (GLMD) - Risers & Fallers - Price Target Update On Galmed Pharmaceuticals Ltd. (GLMD)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Galmed Pharmaceuticals Ltd. (GLMD). Most recent broker ratings. 08/14/2015 – Galmed Pharmaceuticals Ltd. had its “buy” rating reiterated by analysts at SunTrust.
01/28/16 11:45 AMLatest Analysts Reports On Galmed Pharmaceuticals Ltd. (GLMD) - Risers & Fallers - Latest Analysts Reports On Galmed Pharmaceuticals Ltd. (GLMD)Risers & Fallers06/23/2015 – H.C. Wainwright began new coverage on Galmed Pharmaceuticals Ltd. giving the company a “buy” rating. They now have a USD 21 price target on the stock. 04/01/2015 – Galmed Pharmaceuticals Ltd. had its “buy” rating reiterated by analysts ...
01/21/16 11:06 AMGalmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8% - Nasdaq - Galmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8%NasdaqGalmed Pharmaceuticals Ltd.GLMD was a big mover last session, as the company saw its shares rise almost 22% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for ...and more »
01/21/16 07:15 AMGalmed Pharmaceuticals (GLMD) Jumps: Stock Up 21.8% -
01/05/16 07:00 AMGalmed Pharmaceuticals to Present at the Biotech Showcase™ - [PR Newswire] - TEL AVIV, Israel, Jan. 5, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that Josh Blacher, Chief Financial Officer, will present a company overview at the Eighth Annual Biotech Showcase™ conference in San Francisco, California, on Tuesday, January 12, 2016 at 10:30 AM Pacific Standard Time. Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol™, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need, and HIV-associated lipodystrophy and NAFLD.
12/09/15 07:43 AMGalmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol™ for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease - [at noodls] - TEL AVIV, Israel, Dec. 1, 2015/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
12/09/15 07:43 AMGalmed Pharmaceuticals Announces Commencement of Patient Screening for the ARREST Study in Europe, and Reports Third Quarter 2015 Financial Results - [at noodls] - TEL AVIV, Israel, Nov. 9, 2015/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
12/08/15 12:08 PMGALMED PHARMACEUTICALS LTD. Financials -
12/02/15 07:00 AMStockNewsNow.com Publishes New SNNLive Video Interview With Galmed Pharmaceuticals Ltd. - [Marketwired] - StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Josh Blacher, CFO of Galmed Pharmaceuticals Ltd. , a clinical-stage biopharmaceutical company focused ...
11/19/15 08:42 AMActinium: An Interesting Stock In The Small Cap Biotech Space -
11/09/15 07:17 AMGalmed Pharmaceuticals reports 3Q loss -
11/09/15 06:07 AMQ3 2015 Galmed Pharmaceuticals Ltd Earnings Release - Before Market Open -
11/02/15 07:30 AMGalmed Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for November 9, 2015 - [PR Newswire] - TEL AVIV, Israel, Nov. 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization ...
10/09/15 07:15 AMGalmed Pharmaceuticals (GLMD) Jumps: Stock Rises 13.7% -
About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd logoGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate, or FABAC, called aramchol. Its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH), which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center, double-blind, randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance. The Company is engaged in developing aramchol for the treatment of NASH in patients who also suffer from obesity and insulin resistance.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLMD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.77
  • 50 Day Moving Average: $4.70
  • 200 Day Moving Average: $5.75
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $52.95M
  • Current Quarter EPS Consensus Estimate: $-1.52 EPS
Additional Links:
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha